Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study To Determine The Anti-Leukemic Effects Of STI571 In Combination With Ara-C In Patients With Chronic Myelogenous Leukemia In Chronic Phase

NCT00022490 is registered in ClinicalTrials.gov with OHSU Knight Cancer Institute as lead sponsor.

NCT NCT00022490
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00022490 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study To Determine The Anti-Leukemic Effects Of STI571 In Combination With Ara-C In Patients With Chronic Myelogenous Leukemia In Chronic Phase
Lead sponsor
OHSU Knight Cancer Institute
Phase
Phase 2
Overall status
Terminated
Start date
June 30, 2001
Completion date
July 31, 2011
Enrollment
24 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

leukemia